Roche (OTCQX:RHHBY +0.7%) has agreed to collaborate with privately held Waltham, MA-based Arrakis Therapeutics to discover RNA-targeted small molecule drugs against a broad range of targets across its (Roche’s) R&D areas.
Arrakis says it has developed a comprehensive drug discovery toolkit that
adapts the conventional tools of small molecule drug discovery to
address RNA targets instead of proteins while incorporating newly
invented tools to establish a broad structure-based drug design platform
for RNA.
Under the terms of the deal, Arrakis will lead
discovery and research for each target up to a certain point, at which
Roche will have the exclusive option to advance the candidate through
preclinical and clinical development.
Arrakis will receive $190M in upfront cash,
milestones and royalties on net sales, adding that the aggregate value
of future payments “exceeds several billion dollars.”
https://seekingalpha.com/news/3559391-roche-teams-up-arrakis-therapeutics-in-rna-targeted-small-molecules
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.